Aquestive
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aquestive - overview
Established
2005
Location
Warren, NJ, US
Primary Industry
Pharmaceuticals
About
Baseed in the US, Aquestive Therapeutics, Inc. focuses on innovative pharmaceutical solutions, particularly through its proprietary PharmFilm technology, enhancing drug delivery methods to improve patient outcomes in critical health conditions. Based in Warrenton, US, founded in 2005, Aquestive Therapeutics, Inc. is dedicated to developing advanced pharmaceutical products.
The current CEOs are Daniel Barber and Mark Schobel, leading the company since its inception In May 2026, Aquestive raised USD 55 million in venture debt funding from Oaktree Capital Management. Aquestive Therapeutics specializes in innovative drug delivery systems, notably using PharmFilm® technology. Their product line includes Libervant® (diazepam) Buccal Film for managing pediatric seizure clusters and AQST-109, a sublingual film for rapid epinephrine delivery during anaphylactic emergencies. Their solutions target patients with central nervous system conditions and severe allergies, facilitating a more effective treatment experience across North America, Europe, and parts of Asia.
In the most recent fiscal year 2024, Aquestive Therapeutics reported a revenue of USD 57. 56 mn, alongside an EBITDA of USD -19. 34 mn, reflecting their operational focus within the pharmaceutical sector and product distribution through healthcare partnerships. The company plans to use the May 2026 funding to refinance existing debt and support the commercialization of Anaphylm and its development pipeline.
Current Investors
Halifax Group, CNF Investments, Ed Bass Group
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.aquestive.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aquestive - timeline of key events
Aquestive - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 67,430,000 | 52,609,000 | 45,849,000 | 50,832,000 | 47,680,000 | - | - | - |
| % Revenue Growth (YoY) | - | (22.0%) | (12.8%) | 10.9% | (6.2%) | - | - | - |
| EBITDA (USD) | (44,002,000) | (47,834,000) | (36,863,000) | (27,984,000) | (39,464,000) | - | - | - |
| Operating Income (USD) | (48,934,000) | (52,668,000) | (42,893,000) | (34,679,000) | (42,066,000) | - | - | - |
| Operating Margin | (72.6%) | (100.1%) | (93.6%) | (68.2%) | (88.2%) | - | - | - |
| % EBITDA Margin | (65.3%) | (90.9%) | (80.4%) | (55.1%) | (82.8%) | - | - | - |
| NET Income (USD) | (61,376,000) | (66,246,000) | (55,783,000) | (70,539,000) | (54,410,000) | - | - | - |
| % Net Margin | (91.0%) | (125.9%) | (121.7%) | (138.8%) | (114.1%) | - | - | - |
Aquestive - employee data
Aquestive - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.